Theravance Biopharma, Inc. (TBPH) Financials

$13.91

$0.25 (1.83%)
Last update: 04:00 PM EST
Day's range
$13.65
Day's range
$13.93
$100M$100M$0$0-$100M-$100M-$200M-$200M-$300M-$300MEarning201820182019201920202020202120212022202220232023202420240%0%-100%-100%-200%-200%-300%-300%-400%-400%Profit Margin
Profit Margin
Revenue
Earnings

TBPH Income statement / Annual

Last year (2024), Theravance Biopharma, Inc.'s total revenue was $64.38 M, an increase of 12.12% from the previous year. In 2024, Theravance Biopharma, Inc.'s net income was -$56.42 M. See Theravance Biopharma, Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2024 FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015
Period Ended 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Operating Revenue $64.38 M $57.42 M $51.35 M $55.31 M $71.86 M $73.41 M $60.37 M $15.39 M $48.65 M $42.13 M
Cost of Revenue $0.00 $0.00 $6.59 M $7.29 M $260.95 M $219.25 M $715.00 K $6.03 M $2.89 M $4.66 M
Gross Profit $64.38 M $57.42 M $44.76 M $48.03 M -$189.10 M -$145.83 M $59.66 M $9.36 M $45.75 M $37.47 M
Gross Profit Ratio 1 1 0.87 0.87 -2.63 -1.99 0.99 0.61 0.94 0.89
Research and Development Expenses $37.64 M $40.62 M $63.39 M $193.66 M $260.95 M $219.25 M $201.35 M $173.89 M $141.71 M $129.17 M
General & Administrative Expenses $64.87 M $0.00 $59.07 M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Selling & Marketing Expenses $4.30 M $0.00 $8.00 M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $69.17 M $70.10 M $67.07 M $99.30 M $108.66 M $106.08 M $97.06 M $95.59 M $84.51 M $90.20 M
Other Expenses $4.51 M $2.74 M $0.00 $0.00 -$1.61 M $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expenses $111.33 M $113.46 M $130.47 M $292.95 M $369.61 M $325.33 M $298.41 M $269.48 M $226.22 M $219.37 M
Cost And Expenses $111.33 M $113.46 M $130.47 M $292.95 M $369.61 M $325.33 M $299.12 M $275.51 M $229.12 M $224.03 M
Interest Income $4.88 M $9.12 M $8.55 M $1.11 M $2.83 M $8.40 M $11.97 M $4.79 M $1.31 M $631.00 K
Interest Expense $2.55 M $2.35 M $6.37 M $8.55 M $44.59 M $31.86 M $10.48 M $8.55 M $1.40 M $0.00
Depreciation & Amortization $3.62 M $4.26 M $6.59 M $7.29 M $6.64 M $6.52 M $3.17 M $4.03 M $3.12 M $2.99 M
EBITDA -$38.45 M -$42.66 M -$79.86 M -$249.39 M -$294.00 M -$203.29 M -$212.44 M -$259.14 M -$176.04 M -$178.77 M
EBITDA Ratio -0.6 -0.74 -1.56 -4.51 -4.09 -2.77 -3.52 -16.84 -3.62 -4.24
Operating Income Ratio -0.73 -0.98 -1.79 -4.66 -4.14 -3.43 -3.95 -16.91 -3.71 -4.32
Total Other Income/Expenses Net $2.34 M $6.77 M -$858.00 K -$7.44 M $11.22 M $10.24 M $12.67 M -$11.59 M -$92.00 K $631.00 K
Income Before Tax -$44.61 M -$49.27 M -$92.82 M -$199.58 M -$286.54 M -$241.68 M -$226.09 M -$271.71 M -$180.56 M -$181.27 M
Income Before Tax Ratio -0.69 -0.86 -1.81 -3.61 -3.99 -3.29 -3.74 -17.66 -3.71 -4.3
Income Tax Expense $11.80 M $5.92 M $9.00 K -$151.00 K -$8.52 M -$5.22 M -$10.56 M $13.69 M $10.11 M $951.00 K
Net Income -$56.42 M -$55.19 M -$92.82 M -$199.43 M -$278.02 M -$236.46 M -$215.52 M -$285.41 M -$190.67 M -$182.22 M
Net Income Ratio -0.88 -0.96 -1.81 -3.61 -3.87 -3.22 -3.57 -18.55 -3.92 -4.33
EPS -1.15 -1 -1.26 -2.87 -4.46 -4.25 -3.99 -5.45 -4.26 -5.34
EPS Diluted -1.15 -1 -1.26 -2.87 -4.46 -4.25 -3.99 -5.45 -4.26 -5.34
Weighted Average Shares Out $48.85 M $55.30 M $73.59 M $69.46 M $62.35 M $55.61 M $53.97 M $52.35 M $44.71 M $34.15 M
Weighted Average Shares Out Diluted $48.85 M $55.30 M $73.59 M $69.46 M $62.35 M $55.61 M $53.97 M $52.35 M $44.71 M $34.15 M
Link